OLIX PHARMACEUTICALS
OliX is a clinical stage biotechnology company, based on their own proprietary RNA interference (RNAi) technology regulating the expression of disease-causing genes.
OLIX PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2010-02-26
Address:
Suwon, Ch'ungch'ong-namdo, South Korea
Country:
South Korea
Website Url:
http://www.olixpharma.com
Total Employee:
51+
Status:
Active
Contact:
+82-031-779-8400
Email Addresses:
[email protected]
Total Funding:
41.5 B KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Content Delivery Network Mobile Non Scaleable Content Person Schema COVID-19 JQuery CDN IIS DigiCert SSL
Similar Organizations
Aprogen
Aprogen is a unique biotechnology venture
Bharat Biotech
India's second biggest vaccines company
Cellenkos
Cellenkos is a clinical stage biotech company.
Ruidi Bio
Ruidi Biotechnology is a professional biotechnology service company.
Current Employees Featured
Founder
Stock Details
Investors List
Widwin Investment
Widwin Investment investment in Post-IPO Equity - OliX Pharmaceuticals
Aju IB Investment
Aju IB Investment investment in Post-IPO Equity - OliX Pharmaceuticals
NH Investment & Securities
NH Investment & Securities investment in Post-IPO Equity - OliX Pharmaceuticals
Kiwoom Investment
Kiwoom Investment investment in Post-IPO Equity - OliX Pharmaceuticals
Official Site Inspections
http://www.olixpharma.com Semrush global rank: 4.73 M Semrush visits lastest month: 1.98 K
- Host name: naver773.naver.com
- IP address: 211.218.150.117
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "OliX Pharmaceuticals"
OliX Pharmaceuticals - Crunchbase Company Profile
Organization. OliX Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; Phone Number +82-031-779 …See details»
OliX Pharmaceuticals, Inc. | LinkedIn
OliX Pharmaceuticals, Inc. Pharmaceutical Manufacturing Suwon-si, Gyeonggi-do 3,672 followers Contributing to the Health and Happiness of Mankind with RNAi TechnologySee details»
OliX Pharmaceuticals - Craft
Sep 11, 2024 OliX Pharmaceuticals (previously known as BMT) is a biotechnology company. It builds its own proprietary RNA interference (RNAi) technology regulating the expression of …See details»
Driving drug development through next-generation ... - Nature
OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 ...
Dec 22, 2023 SUWON, South Korea, December 22, 2023--OliX Pharmaceuticals, Inc. received approval from the HREC to conduct a Phase 1 clinical trial of drug candidate OLX75016See details»
OliX Pharmaceuticals Announces Positive Safety Data and …
Nov 29, 2023 SUWON, South Korea, November 29, 2023--OliX announced positive results from a Phase 1 study of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).See details»
OliX Announces Completion of USD 45 Million Capital ... - Business …
May 25, 2022 Media Contact: Jiyoun Kim OliX Pharmaceuticals PR +82-2-3489-4801 [email protected]. Site Navigation. Home. Home; Submit a Press Release; Services; …See details»
OliX Pharmaceuticals and PCI Biotech announce a collaboration to ...
May 5, 2021 For more information, please visit: www.pcibiotech.com Contact Information: OliX Pharmaceuticals Media ContactKelly Kim / CommunicationsPhone: +82 10 4220 2801E-Mail: …See details»
OliX Pharmaceuticals Receives IND Approval from FDA to Develop …
Aug 3, 2022 Media Contact: Jiyoun Kim OliX Pharmaceuticals PR +82-2-3489-4801 [email protected] Release Summary FDA has approved the OliX Pharmaceuticals' …See details»
OliX Announces Completion of $37.2 Million Capital Raise to
Dec 1, 2020 Capital to fund construction of RNA synthesis GMP facility in San Diego; Supports company’s goal of having 10 programs entered into clinical trials by 2024See details»
OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical ...
Jun 13, 2023 Media Contact: Jiyoun Kim OliX Pharmaceuticals PR +82-2-3489-4801 [email protected] Release Summary OliX administers 1st patient in Phase 1 clinical …See details»
OliX Pharmaceuticals Signs Agreement with LGC Biosearch
Jun 9, 2021 SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and …See details»
OliX Pharmaceuticals and PCI Biotech announce a - GlobeNewswire
May 5, 2021 E-Mail: [email protected]. PCI Biotech Holding ASA Per Walday, CEO Mobile: +47 917 93 429 E-Mail: [email protected]. Forward-looking statements ...See details»
OliX Pharmaceuticals Announces Positive Results from a Phase 2a …
Apr 28, 2023 Media Contact: Jiyoun Kim OliX Pharmaceuticals PR +82-2-3489-4801 [email protected]. Release Summary. OliX reported positive phase 2a trial results for …See details»
OliX Pharmaceuticals Announces IND Submission to U.S. FDA to …
Jul 1, 2022 OliX Pharmaceuticals announced the submission of an IND application of OLX10212 for the treatment of age-related macular degeneration to the FDA.See details»
OliX Pharmaceuticals Announces FDA Clearance of the IND to
Oct 30, 2020 Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to-date; Phase 2a trial follows the successful completion of OliX’s Phase 1 trial in …See details»
OliX Pharmaceuticals Announces Positive Safety Data and …
Nov 29, 2023 Media Contact: Jiyoun Kim OliX Pharmaceuticals PR +82-2-3489-4801 [email protected] Release Summary OliX announced positive results from a Phase …See details»
OliX Pharmaceuticals to Present at 2021 Oligonucleotide
Sep 24, 2021 SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today …See details»
OliX Pharmaceuticals Identifies Effective Inhibition of Target Gene ...
May 4, 2022 Jiyoun Kim OliX Pharmaceuticals PR +82-2-3489-4800 [email protected] Release Summary OliX Pharmaceuticals identified effective inhibition of target gene …See details»